CAMBRIDGE, Mass., March 8, 2024 /PRNewswire/ — Regor Therapeutics Group (“Regor”), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that its Phase 2 trial of the highly…